Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Kevin Obrien

Allergy & Immunology Thornton, CO Medical Doctor

NPI 1134131733 CMS profile 395255

3260 E 104Th Ave, Thornton, CO 80233

Open in the dashboard

General payments

$12,826

189 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,718,386 paid to institutions, not to them · program years 2020–2025

Through program year 2022, Kevin Obrien of Thornton, CO is reported in the CMS Open Payments database as having received $12,826 across 189 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,718,386 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $500 24
2021 General $3,161 54
2020 General $2,621 53
2019 General $6,543 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Obrien
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Kevin Obrien were reported at $0. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Kevin Obrien Allergy & Immunology median Middle half National median
2019 $6,543 $378 $115–$1,178 $163
2020 $2,621 $303 $75–$1,581 $114
2021 $3,161 $407 $122–$1,475 $132
2022 $500 $357 $120–$1,340 $149
2023 $0 $445 $124–$1,536 $160
2024 $0 $541 $129–$1,763 $164
2025 $0 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. BioCryst Pharmaceuticals, Inc. $7,507 15 payments
  2. BioCryst US Sales Co., LLC $2,010 12 payments
  3. Genzyme Corporation $623 18 payments
  4. GlaxoSmithKline, LLC. $551 36 payments
  5. AstraZeneca Pharmaceuticals LP $380 23 payments
  6. Grifols USA, LLC $347 16 payments
  7. Regeneron Healthcare Solutions, Inc. $319 18 payments
  8. CSL Behring $277 11 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $180 6 payments
  10. Novartis Pharmaceuticals Corporation $104 6 payments
  11. Other $528 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Honoraria $4,650 2 payments
  2. Consulting Fee $3,765 4 payments
  3. Food and Beverage $3,161 178 payments
  4. Travel and Lodging $900 4 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $350 1 payment
Products named General payments · program years 2019–2022
  1. Orladeyo $2,010 12 payments
  2. DUPIXENT Immunology $746 25 payments
  3. DUPIXENT Inflammation And Immunology $319 18 payments
  4. NUCALA Immunology $296 14 payments
  5. DUPIXENT Immunology $236 14 payments
  6. FASENRA $202 11 payments
  7. Hizentra $170 6 payments
  8. Prolastin-C Liquid $154 8 payments
  9. NUCALA Respiratory $137 14 payments
  10. Gamunex-C $135 5 payments
  11. Other $1,225 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record